Compare Mondaycom Ltd (MNDY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Merck & Co., Inc. — how do they compare? Mondaycom Ltd trades at $88.92 (market cap $3.76B), while Merck & Co., Inc. trades at $146.05 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 93.4× Mondaycom Ltd's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Merck & Co., Inc. for 98 Days on average.
| MNDY | MRK | |
|---|---|---|
Market Cap | $3.76B | $351.28B |
Volume | 836,200 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $205.24 | $156.43 |
52-Week Low | $58.81 | $82.49 |
Typical Hold Time | 16 Days | 98 Days |
Enterprise Value | $2.92B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $88.41, up 5.87% in the last session, showing strong momentum near 52-week highs. The stock maintains a bullish technical outlook with consistent earnings beats and robust revenue growth. Recent Q2 2026 EPS of $1.48 exceeded expectations by 33%, while enterprise customer growth accelerated to 37% year-over-year. The company's Elevate '26 conference highlights AI integration efforts, positioning it for continued market share gains in the work management software sector.
With 65% analyst buy ratings and a $108.64 consensus price target, MNDY offers 23% upside potential. However, elevated valuation multiples (P/E 37.7, EV/EBITDA 53.5) and increasing competition from Meta's enterprise push present near-term risks. The stock's current RSI near 88 suggests overbought conditions, though fundamental growth drivers remain intact for long-term investors.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
